The launch of GlaxoSmithKline PLC's shingles vaccines Shingrix is tracking to be a very successful commercial product for the big pharma, one that is coming just in time to help the company navigate the loss of its one-time pillar Advair Diskus (fluticasone/salmeterol).
Mylan's launch of the first generic version of the blockbuster asthma drug in February negatively impacted first-quarter sales of branded...








